Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Reaches New 12-Month High – What’s Next?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $10.50 and last traded at $10.35, with a volume of 37248 shares traded. The stock had previously closed at $10.00.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Performance

The stock has a market cap of $23.12 billion, a price-to-earnings ratio of 49.29 and a beta of 1.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.36 and a quick ratio of 1.05. The firm has a fifty day moving average of $9.41 and a 200 day moving average of $9.23.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last issued its earnings results on Wednesday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $6.01 billion during the quarter. As a group, sell-side analysts forecast that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.